Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542564 | 0.86 | LMNA (0.64) | LMNAKMT2AMEN1ADAM17TNKS | |
| SCHEMBL542398 | 0.83 | LMNA (0.55) | LMNAAKR1B1KMT2AMEN1TNKS | |
| SCHEMBL542150 | 0.82 | LMNA (0.59) | LMNAKMT2AMEN1ADAM17TNKS | |
| SCHEMBL20135360 | 0.79 | LMNA (0.59) | LMNAKMT2AMEN1ADAM17MAPT | |
| SCHEMBL29688389 | 0.79 | LMNA (0.59) | LMNAKMT2AMEN1ADAM17MAPT | |
| SCHEMBL542810 | 0.79 | LMNA (0.56) | LMNAKMT2AMEN1ADAM17GAA | |
| SCHEMBL29949272 | 0.79 | LMNA (0.51) | LMNAKMT2AMEN1TNKSMMP2 | |
| SCHEMBL11094849 | 0.78 | LMNA (0.45) | LMNAAKR1B1KMT2AMEN1GAA | |
| SCHEMBL542334 | 0.77 | LMNA (0.53) | LMNAKMT2AMEN1ADAM17 | |
| SCHEMBL20134874 | 0.76 | LMNA (0.56) | LMNAKMT2AMEN1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168667-B2 | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such | GALAPAGOS NV (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2026799-B1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | DART THERAPUTICS, LLC. | 2010-08-19 | — | — | US | disclosed |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | SASU, GALAPAGOS (FR) | 2010-03-11 | — | — | US | disclosed |
| EP-2026799-A2 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | Galapagos SAS (FR) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007137874-A2 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | NR5A1, AR, HSD17B7 | LMNA 4085/4885AKR1B1 56/4885KMT2A 1222/4885 |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | NR5A1, AR, HSD17B7 | LMNA 4071/4885AKR1B1 56/4885KMT2A 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.